Holen Sie sich die Stockscreener-App
4.135
6.57%
0.255
Handel nachbörslich:
4.22
0.085
+2.06%
Schlusskurs vom Vortag:
$3.88
Offen:
$3.9
24-Stunden-Volumen:
25,886
Relative Volume:
0.75
Marktkapitalisierung:
$16.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.67M
KGV:
-1.3382
EPS:
-3.09
Netto-Cashflow:
$-101.06M
1W Leistung:
+4.42%
1M Leistung:
-10.11%
6M Leistung:
+1,185%
1J Leistung:
+604.43%
1-Tages-Spanne:
$3.90
$4.17
1-Wochen-Bereich:
$3.8001
$4.17
52-Wochen-Spanne:
$0.2195
$5.00
Athira Pharma Inc Stock (ATHA) Company Profile
Firmenname
Athira Pharma Inc
Sektor
Branche
Telefon
(425) 620-8501
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Vergleichen Sie ATHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
4.135 | 15.30M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-04 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-09-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-10-17 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-23 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Eingeleitet | BTIG Research | Buy |
| 2022-04-21 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Goldman | Neutral |
| 2020-10-13 | Eingeleitet | Goldman | Buy |
| 2020-10-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-13 | Eingeleitet | Jefferies | Buy |
| 2020-10-13 | Eingeleitet | Stifel | Buy |
Alle ansehen
Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten
Contrasting Day One Biopharmaceuticals (NASDAQ:DAWN) & Athira Pharma (NASDAQ:ATHA) - Defense World
Entry Recap: Will Athira Pharma Inc stock outperform growth indexesJuly 2025 Update & Free Risk Controlled Daily Trade Plans - moha.gov.vn
How Athira Pharma Inc. stock trades before earningsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Will Athira Pharma Inc. stock outperform growth indexes2025 Market Overview & Accurate Buy Signal Alerts - Newser
Alzheimer's Disease Market to Evolve Rapidly Over the Next - openPR.com
What analysts say about Athira Pharma Inc stockIndustrial Stocks Review & Start Learning With Our Courses - earlytimes.in
Why Athira Pharma Inc. stock could benefit from AI revolutionJuly 2025 Summary & High Yield Equity Trading Tips - newser.com
How Athira Pharma Inc. stock performs during Fed tightening cycles2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Athira Pharma Inc. stock outlook for YEARGap Up & Weekly Market Pulse Updates - newser.com
Why Athira Pharma Inc. stock is popular among millennialsEarnings Trend Report & Daily Oversold Stock Bounce Ideas - newser.com
How to escape a deep drawdown in Athira Pharma Inc.Earnings Growth Summary & Consistent Return Strategy Ideas - newser.com
What makes Athira Pharma Inc. stock attractive to growth fundsJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Will Athira Pharma Inc. stock benefit from AI adoption2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Top chart patterns to watch in Athira Pharma Inc.July 2025 EndofMonth & Real-Time Volume Triggers - newser.com
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC) - The Globe and Mail
What indicators show strength in Athira Pharma Inc.July 2025 Pullbacks & Capital Efficient Trade Techniques - newser.com
What analyst consensus says on Athira Pharma Inc. stock2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Will Athira Pharma Inc. continue its uptrendEarnings Growth Report & Real-Time Chart Breakout Alerts - newser.com
Update Recap: Is Athira Pharma Inc. stock ready for breakoutBull Run & Daily Chart Pattern Signal Reports - Fundação Cultural do Pará
ATHA | Athira Pharma Inc. SEC Filings - MarketWatch
Risk vs reward if holding onto Athira Pharma Inc.Quarterly Growth Report & Accurate Intraday Trading Signals - newser.com
Athira Pharma Inc. stock volume spike explainedWeekly Profit Report & Weekly Consistent Profit Watchlists - newser.com
Can Athira Pharma Inc. stock deliver consistent earnings growthDollar Strength & Long-Term Growth Portfolio Plans - newser.com
Real time alert setup for Athira Pharma Inc. performanceRate Cut & Consistent Return Strategy Ideas - newser.com
Is Athira Pharma Inc. stock cheap at current valuationJuly 2025 Review & Weekly Stock Performance Updates - newser.com
Finanzdaten der Athira Pharma Inc-Aktie (ATHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Athira Pharma Inc-Aktie (ATHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
168,901 |
| Litton Mark James | President and CEO |
Jun 30 '25 |
Option Exercise |
0.00 |
108,334 |
0 |
350,925 |
| Litton Mark James | President and CEO |
Jul 01 '25 |
Sale |
0.29 |
25,123 |
7,374 |
325,802 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
46,666 |
0 |
82,507 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
0.29 |
10,842 |
3,182 |
71,665 |
| Worthington Mark | General Counsel and CCO |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
120,401 |
| Worthington Mark | General Counsel and CCO |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
111,875 |
| Renninger Robert | SVP, Finance and Accounting |
Jun 30 '25 |
Option Exercise |
0.00 |
12,359 |
0 |
112,083 |
| Renninger Robert | SVP, Finance and Accounting |
Jul 01 '25 |
Sale |
0.29 |
2,897 |
850 |
109,186 |
0.18%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):